SCHEMBL13374396

SCHEMBL13374396

CC(C)(C)CCCCNC(=O)CC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.40
CASP2 P42575 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
FFAR1 O14842 1/20 0.39
CPT2 P23786 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MAPK1 P28482 1/20 0.38
HIF1A Q16665 1/20 0.38
NAAA Q02083 1/20 0.37
POLB P06746 1/20 0.35
HSD17B10 Q99714 2/20 0.35
BRD4 O60885 1/20 0.34
EPHX1 P07099 2/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22664218 0.98 MEN1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL24193577 0.98 MEN1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL25876080 0.98 MEN1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL25475907 0.98 MEN1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL13374400 0.94 MEN1 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL23518488 0.89 MEN1 (0.52) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL20198781 0.85 SIGMAR1 (0.50) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL22664217 0.83 FFAR1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL21015239 0.83 MEN1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2CASP2
SCHEMBL20121987 0.83 CASP2 (0.59) MEN1KMT2AALDH1A1SMN1; SMN2CASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
US-20220175722-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-06-09 US disclosed
US-10301324-B2 Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use Atrin Pharmaceuticals LLC (US) 2019-05-28 US disclosed
US-9950064-B2 Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2018-04-24 US disclosed
US-20170291911-A1 Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use Atrin Pharmaceuticals LLC 2017-10-12 US disclosed
US-20170291911-A1 Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use Atrin Pharmaceuticals LLC 2017-10-12 US disclosed
US-20160213774-A1 BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF DYNAVAX TECHNOLOGIES CORPORATION 2016-07-28 US disclosed
US-20130203659-A1 GLP-1 COMPOUNDS MIRANDA LESLIE P (US) 2013-08-08 US disclosed
US-8288339-B2 GLP-1 compounds AMGEN INC. (US) 2012-10-16 US disclosed
US-20100048468-A1 GLP-1 COMPOUNDS AMGEN INC. (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213774-A1 BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF PAICS, PBK, PHAX MEN1 3016/4885KMT2A 2816/4885ALDH1A1 4448/4885
US-20220175722-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FGFR2, FGF2, FGFR1 MEN1 3032/4885KMT2A 618/4885ALDH1A1 2103/4885
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME PSMA6, PSMC1, PSMA1 MEN1 3479/4885KMT2A 1544/4885ALDH1A1 4341/4885
US-10301324-B2 Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use ATR, CHEK2, CHEK1 MEN1 1307/4885KMT2A 1652/4885ALDH1A1 4748/4885
US-20100048468-A1 GLP-1 COMPOUNDS GLP1R, IAPP, GIPR MEN1 169/4885KMT2A 3312/4885ALDH1A1 3928/4885
US-20130203659-A1 GLP-1 COMPOUNDS GLP1R, IAPP, GIPR MEN1 169/4885KMT2A 3312/4885ALDH1A1 3928/4885
US-20170291911-A1 Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use ATR, CHEK2, CHEK1 MEN1 1307/4885KMT2A 1652/4885ALDH1A1 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.